NeuroSense Financial Statements From 2010 to 2025

NRSNW Stock  USD 0.20  0.02  9.09%   
NeuroSense Therapeutics financial statements provide useful quarterly and yearly information to potential NeuroSense Therapeutics Ltd investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NeuroSense Therapeutics financial statements helps investors assess NeuroSense Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NeuroSense Therapeutics' valuation are summarized below:
Earnings Share
(0.94)
There are over one hundred nineteen available fundamental ratios for NeuroSense Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should check NeuroSense Therapeutics' last-minute fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Enterprise Value is likely to climb to about 12.9 M in 2025, whereas Market Cap is likely to drop slightly above 6.9 M in 2025.
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 214.9 K, Depreciation And Amortization of 117.1 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
  
Check out the analysis of NeuroSense Therapeutics Correlation against competitors.
For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

NeuroSense Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.3 M3.7 M2.6 M
Slightly volatile
Other Current Liabilities2.3 M2.2 M525.6 K
Slightly volatile
Total Current Liabilities4.2 MM901.7 K
Slightly volatile
Property Plant And Equipment Net287.4 K273.7 K75.4 K
Slightly volatile
Accounts Payable1.8 M1.7 M357.5 K
Slightly volatile
Cash4.1 MM2.1 M
Slightly volatile
Non Current Assets Total154 K299 K95.7 K
Slightly volatile
Non Currrent Assets Other23.4 K19.8 K31.1 K
Slightly volatile
Cash And Short Term Investments4.9 MM2.4 M
Slightly volatile
Net Receivables115.1 K190.9 K61.9 K
Slightly volatile
Common Stock Shares Outstanding16.5 M15.7 MM
Slightly volatile
Liabilities And Stockholders Equity5.3 M3.7 M2.6 M
Slightly volatile
Other Current Assets97 K126.5 K41.5 K
Slightly volatile
Other Stockholder Equity18 M34.7 M9.8 M
Slightly volatile
Total Liabilities6.1 M5.8 M1.4 M
Slightly volatile
Property Plant And Equipment Gross333.3 K317.4 K85 K
Slightly volatile
Total Current Assets5.1 M3.4 M2.5 M
Slightly volatile
Accumulated Other Comprehensive Income18 M34.7 M9.8 M
Slightly volatile
Common Stock800900981
Slightly volatile
Short and Long Term Debt Total121.4 K127.8 K1.4 M
Slightly volatile
Short Term Debt73.2 K79.3 K65.8 K
Slightly volatile

NeuroSense Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense379.5 K632.5 K173.9 K
Slightly volatile
Selling General Administrative3.3 M5.5 M1.7 M
Slightly volatile
Other Operating Expenses7.4 M11.8 MM
Slightly volatile
Research Development4.4 M8.4 M2.6 M
Slightly volatile
Total Operating Expenses7.4 M11.8 MM
Slightly volatile
Total Other Income Expense Net792 K884.4 K337.1 K
Slightly volatile
Cost Of Revenue117.1 K111.5 K28.2 K
Slightly volatile
Selling And Marketing Expenses4.5 M5.1 M5.5 M
Slightly volatile

NeuroSense Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based CompensationM1.8 M1.5 M
Slightly volatile
Change In Working Capital2.3 M2.2 M486.8 K
Slightly volatile
Begin Period Cash Flow3.6 M4.1 M1.5 M
Slightly volatile
Capital Expenditures29 K33.4 K16.1 K
Slightly volatile
Total Cash From Financing Activities4.7 M4.5 M2.7 M
Slightly volatile
End Period Cash Flow4.1 MM2.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.330.344.3597
Slightly volatile
Payables Turnover0.07540.05980.0661
Slightly volatile
Cash Per Share0.210.220.7444
Pretty Stable
Days Payables Outstanding5.2 K6.3 K6.1 K
Slightly volatile
Income Quality0.390.670.4883
Pretty Stable
Net Debt To EBITDA0.260.270.7254
Very volatile
Current Ratio0.920.9717.4348
Slightly volatile
Graham Number1.651.743.0645
Pretty Stable
Capex Per Share0.00230.00240.0039
Very volatile
Interest Debt Per Share0.04340.04570.1076
Pretty Stable
Debt To Assets0.0850.05140.133
Slightly volatile
Days Of Payables Outstanding5.2 K6.3 K6.1 K
Slightly volatile
Ebt Per Ebit1.01.080.9702
Pretty Stable
Long Term Debt To Capitalization0.02040.02290.025
Slightly volatile
Quick Ratio0.920.9717.587
Slightly volatile
Net Income Per E B T0.981.030.967
Slightly volatile
Cash Ratio0.830.8816.9234
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0261
Slightly volatile
Debt Ratio0.0850.05140.133
Slightly volatile

NeuroSense Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.9 M12.6 M8.7 M
Slightly volatile

NeuroSense Fundamental Market Drivers

Cash And Short Term Investments2.6 M

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue111.5 K117.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.

Trending Assets

GOVXW
GeoVax Labs
0.06  -0.0074  -11.38 
NRSN
Neurosense Therapeutics
1.11  0.04  3.74 
KTTAW
Pasithea Therapeutics
0.02  -0.0026  -10.48 
CINGW
Cingulate Warrants
0.03  -0.009  -21.28 
News Freq…Investor S…